[3-Hydroxy-3-(3-pyridinyl)propyl]carbamic acid, 1,1-dimethylethyl ester | 357405-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: [3-Hydroxy-3-(3-pyridinyl)propyl]carbamic acid, 1,1-dimethylethyl ester
• 英文别名: [3-Hydroxy-3-(3-pyridinyl)propyl]carbamic acid 1,1-dimethylethyl ester；tert-butyl N-(3-hydroxy-3-pyridin-3-ylpropyl)carbamate
• CAS: 357405-01-7
• 化学式: C₁₃H₂₀N₂O₃
• 分子量: 252.313
• InChiKey: ZZGSNPVSIBBOKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  71.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  sodium;hydride 、 [3-Hydroxy-3-(3-pyridinyl)propyl]carbamic acid, 1,1-dimethylethyl ester 、 4-氯-2,5-二氟苯腈 、 在 氯化铵 、 乙酸乙酯 、 Sodium sulfate-III 、 silica 、 petrol—acetone 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以to give 1.05 g (88%) of the sub-title compound as a colourless oil的产率得到(3-(5-Chloro-2-cyano-4-fluorophenoxy)-3-(3-pyridinyl)propyl]carbamic acid 1,1 dimethylethyl ester
  参考文献：
  名称：

  Use of phenylheteroakylamine derivatives

  摘要：

  本发明揭示了使用化合物(I)的方法，其中R1、R2、X、Y、V、W和Z在说明书中有定义，并且其药学上可接受的盐、对映体或外消旋体，用于制造药物，用于治疗或预防抑制一氧化氮合酶活性对疾病或情况有益的疾病或情况。本发明揭示了某些新型化合物(Ia)及其药学上可接受的盐、对映体和外消旋体，以及它们的制备方法、含有它们的组合物以及它们在治疗中的应用。化合物(I)和(Ia)是一氧化氮合酶酶的抑制剂，因此在治疗或预防炎症性疾病方面特别有用。

  公开号：

  US06887871B2

文献信息

• Novel use of phenylheteroakylamine derivatives
  申请人：——

  公开号：US20030158185A1

  公开（公告）日：2003-08-21

  There is disclosed the use of a compound of formula (I) wherein R 1 , R 2 , X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.

  公开了使用式（I）的化合物，其中R1、R2、X、Y、V、W和Z如规范中定义，并且其药学上可接受的盐、对映体或消旋体，在制备药物时用于治疗或预防抑制一氧化氮合酶活性有益的疾病或症状。公开了式（Ia）的某些新化合物及其药学上可接受的盐，以及其对映体和消旋体；以及它们的制备方法、含有它们的组合物以及它们在治疗中的应用。式（I）和（Ia）的化合物是一氧化氮合酶酶的抑制剂，因此在治疗或预防炎症性疾病方面特别有用。
• 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension,cardiovascular or renal diseases
  申请人：Bezencon Olivier

  公开号：US20050176700A1

  公开（公告）日：2005-08-11

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

  本发明涉及式(I)的新型3,9-二氮杂双环[3.3.1]壬烯衍生物及其相关化合物，以及它们作为药物组分在制备药物组合物中的应用。本发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组合物，尤其是它们作为肾素抑制剂的应用。
• NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES
  申请人：AstraZeneca AB

  公开号：EP1263711A1

  公开（公告）日：2002-12-11
• US6887871B2
  申请人：——

  公开号：US6887871B2

  公开（公告）日：2005-05-03
• [EN] NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES<br/>[FR] NOUVELLE UTILISATION DES DERIVES DE PHENYLHETEROALKYLAMINE
  申请人：ASTRAZENECA AB

  公开号：WO2001062704A1

  公开（公告）日：2001-08-30

  There is disclosed the use of a compound of formula (I) wherein R1, R2, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.